1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Is AstraZeneca/Sanofi Library Exchange Open Innovation's Future?

 
• By Sten Stovall

Taking collaboration to a new level within Big Pharma, AstraZeneca PLC and Sanofi SA have agreed to share 210,000 of their proprietary chemical compounds from their respective libraries in a bid to increase the number of leads for new medicines. No money will change hands, both companies will be free to use the compounds without restriction, and any profits resulting from one of the two's successful development of a drug using the library would not be shared.

Taking collaboration to a new level within Big Pharma, AstraZeneca PLC and Sanofi SA have agreed to share 210,000 of their proprietary chemical compounds from their respective libraries in a bid to increase the number of leads for new medicines. No money will change hands, both companies will be free to use the compounds without restriction, and any profits resulting from one of the two's successful development of a drug using the library would not be shared.

AstraZeneca and Sanofi each selected the compounds to exchange based on differences from those in their own libraries. The companies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

More from Therapy Areas

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.